872P Safety and efficacy of toripalimab combined with cetuximab in PD-L1 positive untreated recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC): A phase Ib/II study.

Authors :: Guo, Y.
Li, D.Z.
Lin, J.
Sun, C.
Cao, G.
Wu, J.
Ge, M.
Hu, D.
Qu, S.
Shen, L.
Wei, Y.
Zong, J.
Fang, M.
Jin, C.
Li, Z-M.
Sun, Y.
Wang, X.
Zhang, H.
Wang, W.
Zhu, Y.
Source :: Annals of Oncology. 2024 Supplement 2, Vol. 35, pS625-S625. 1p.
Publication Year :: 2024

Subjects :: *SQUAMOUS cell carcinoma
*PROGRAMMED death-ligand 1
*CETUXIMAB
*NECK
*METASTASIS

Full Text Access

Tools